NRD
TBPH icon

Nebula Research & Development’s Theravance Biopharma TBPH Stock Holding History

Nebula Research & Development’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18,154
Closed -$154K – 1159
2024
Q2 		$154K Buy
+18,154
New +$164K 0.02% 753
2023
Q3 		– Sell
-31,472
Closed -$326K – 656
2023
Q2 		$326K Buy
+31,472
New +$348K 0.25% 197

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Nebula Research & Development's TBPH Position: Q3 2024 in Review

Nebula Research & Development sold out of Theravance Biopharma (TBPH) in Q3 2024, closing a stake of 18,154 shares — an estimated $154K sold.

Nebula Research & Development first reported a position in TBPH in Q2 2023 and held it in 2 quarters. The position peaked at $326K in Q2 2023. 119 funds tracked by Wall St. Rank hold TBPH as of Q3 2024.

  • Nebula Research & Development reported no remaining Theravance Biopharma position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 18,154 Theravance Biopharma shares in Q3 2024, an estimated $154K.
  • Nebula Research & Development first reported a position in Theravance Biopharma in Q2 2023 and held it in 2 quarters.
  • Nebula Research & Development's Theravance Biopharma position peaked at $326K in Q2 2023.
  • 119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.